| Literature DB >> 35663202 |
Ismail Mahdi1, Widad Ben Bakrim1,2, Gabin Thierry M Bitchagno1, Hassan Annaz1, Mona F Mahmoud3, Mansour Sobeh1.
Abstract
Growing concern for public health has increased the need to change the paradigm towards a healthcare system that advocates holistic practices while reducing adverse effects. Herbal therapy is becoming an integral part of the therapeutic arsenal, and several successful plant-derived compounds/molecules are being introduced into the market. The medicinal plants belonging to the genus Thymus are among the most important species within the Lamiaceae family. One of them is Thymus algeriensis which is mainly distributed in the Mediterranean region. For a long time, this species has been used in traditional medicine to treat several disorders and diseases including inflammation, diabetes, rheumatism, digestive, and respiratory affections. This review describes the traditional uses, phytochemical composition, and biological and pharmacological activities of T. algeriensis extracts. Data were obtained using electronic databases such as SciFindern, ScienceDirect, Scopus, and Web of Science. Several plant-based extracts and a broad spectrum of identified secondary metabolites were highlighted and discussed with respective activities and modes of action. T. algeriensis represents a promising natural resource for the pharmaceutical industry mainly for antioxidant, anti-inflammatory, antimicrobial, and anticancer activities. Considering these findings, more research is needed to transmute the conventional uses of T. algeriensis into scientifically sound information. Moreover, extensive preclinical, clinical, toxicological, and pharmacokinetic trials on this species and its derivatives compounds are required to underpin the mechanisms of action and ensure its biosafety and efficiency. This comprehensive review provides a scientific basis for future investigations on the use of T. algeriensis and derived compounds in health maintenance and promotion and disease prevention.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35663202 PMCID: PMC9159826 DOI: 10.1155/2022/6487430
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1Map of distribution of T. algeriensis Boiss. & Reut. across North Africa.
Figure 2(a) Thymus algeriensis Boiss. & Reut. plant; (b) aerial part of Thymus algeriensis Boiss. & Reut. (Source: https://www.biodiversidadvirtual.org/).
Figure 3Flavonoids identified from T. algeriensis.
Chemical constituents of T. algeriensis extracts.
| Compound name | Extract type | Ref. |
|---|---|---|
|
| ||
| Apigenin-6,8- | H2O & EtOH–H2O | [ |
| Apigenin-7- | H2O & EtOH–H2O | [ |
| Aringina | EtOH | [ |
| Baicalinb | n–BuOH | [ |
| Benzoic acidb | H2O | [ |
| Caffeoyl rosmarinic acida | MeOH–H2O | [ |
| Chlorogenic acidb | H2O | [ |
| Clovane-2,9-diola | MeOH | [ |
| Diosminb | n–BuOH | [ |
| Ellagic acida | EtOH | [ |
| Fumaric acidb | n–BuOH | [ |
| Gentisic acidb | n–BuOH | [ |
| Hesperidinb | n–BuOH | [ |
| Isovanillinb | EtOH–H2O & H2O | [ |
| Kaempferol- | H2O & EtOH–H2O | [ |
| Lithospermic acidb | H2O & EtOH–H2O | [ |
| Luteolin glucuronidea | MeOH | [ |
| Methyl ursolatea | MeOH | [ |
| Naringinb | EtOH–H2O, H2O, & n–BuOH | [ |
| Neohesperidinb | n–BuOH | [ |
|
| H2O | [ |
| Oleanolic acida | MeOH | [ |
|
| EtOH–H2O, H2O | [ |
| Epicatechina | EtOH | [ |
| Rosmarinic acid glucosidea | MeOH | [ |
| Salvianolic acid Kab | MeOH, H2O, & EtOH–H2O | [ |
| Scutellarinb | n–BuOH | [ |
| Sinapinic acidb | EtOH–H2O, H2O | [ |
|
| H2O | [ |
| Ursolic acida | MeOH | [ |
|
| MeOH | [ |
| 2,5-Dihydroxybenzoic acida | EtOH | [ |
| 2,3-Dimethoxybenzoic acidb | EtOH–H2O, H2O | [ |
| 3-Hydroxybenzoic acidb | EtOH–H2O, H2O | [ |
| 4-Hydroxybenzoic acidb | H2O, EtOH–H2O, & n–BuOH | [ |
|
| ||
| Catechinb | H2O | [ |
| Gallic acidb | H2O & MeOH | [ |
| Kaempferolab | MeOH–H2O, H2O, & MeOH | [ |
| Quercetinb | H2O & MeOH | [ |
| Rosmarinic acidab | MeOH–H2O & MeOH | [ |
| Rutinab | EtOH–H2O, H2O, & MeOH | [ |
| Syringic acidb | H2O & MeOH | [ |
| Vanillic acidab | EtOH, MeOH, & H2O | [ |
| Epicatechinb | EtOH–H2O & H2O | [ |
|
| ||
| Gallic acidb | H2O | [ |
| Naringeninb | [ | |
| Coumaric acidb | [ | |
| Caffeic acidb | MeOH | [ |
| Ferulic acidb | [ | |
| Flavoneb | [ | |
| Hydroxyphenylic acidb | [ | |
| Methyl gallateb | [ | |
| (+)-Catechin hydrateb | [ | |
| Carvacrola | [ | |
| Kaempferol- | [ | |
| Kaempferol- | [ | |
| Apigeninb | H2O, MeOH | [ |
aLeaves, baerial parts.
Chemical constituents of T. algeriensis essential oils (EO).
| Compound name | Plant part | Quantity (%) | Country | Ref. |
|---|---|---|---|---|
| 1,8-Cineole | Aerial parts | 17.70% | Tunisia | [ |
| 7.55-22.07% ∗ | [ | |||
| 20.98% | [ | |||
| 19.96% | [ | |||
| Leaves | 11.60% | [ | ||
| 12.05% | [ | |||
| Flowers | 9.12% | [ | ||
| Leaves and flowers | 5.54% | [ | ||
| 5.16-11.21%∗∗ | Algeria | [ | ||
| 7.69% | [ | |||
| 6.00% | [ | |||
| 5.94% | [ | |||
| 4-Terpineol | Aerial parts | 1.55-11.86%∗ | Tunisia | [ |
| Leaves and flowers | 7.36% | [ | ||
| Borneol | Aerial parts | 11.16-22.2%∗∗ | Algeria | [ |
| 5.74% | [ | |||
| Stem bark | 11.16% | [ | ||
| Aerial parts | 28% | Morocco | [ | |
| 18.30% | [ | |||
| 23.48% | [ | |||
| 59% | [ | |||
| Camphene | Aerial parts | 7.53-12.86%∗∗ | Algeria | [ |
| Stem bark | 12.78% | [ | ||
| Aerial parts | 20.90% | Morocco | [ | |
| 11.80% | [ | |||
| Camphor | Aerial parts | 17.45-32.56%∗∗ | Algeria | [ |
| 13.62% | [ | |||
| 14.22% | [ | |||
| 17.68% | [ | |||
| Stem bark | 22.60% | [ | ||
| Aerial parts | 15.70% | Morocco | [ | |
| 10.00% | [ | |||
| 27.70% | [ | |||
| 27.70% | [ | |||
| 27.70% | [ | |||
| 19.20% | Tunisia | [ | ||
| 6.8-19.93%∗ | [ | |||
| 7.46% | [ | |||
| 13.82% | [ | |||
| 8.20% | [ | |||
| Leaves | 10.40% | [ | ||
| Leaves and flowers | 7.82% | [ | ||
| Carvacrol | Aerial parts | 48.40% | Algeria | [ |
| 28.10% | [ | |||
| Leaves | 64.6-65.9%¥ | [ | ||
| 4% | [ | |||
| Aerial parts | 80.90% | Libya | [ | |
| 14% | [ | |||
| 4.59% | [ | |||
| 36.78% | [ | |||
| Aerial parts | 85% | Morocco | [ | |
| Caryophyllene oxide | Stems | 17.80% | Tunisia | [ |
| Roots | 21.10% | [ | ||
| cis-Sabinene hydrate | Aerial parts | 0.10-12.95%∗ | Tunisia | [ |
| Leaves and flowers | 5.29% | [ | ||
| Elemol | Aerial parts | 18.38% | Algeria | [ |
| Leaves | 3.98% | Tunisia | [ | |
| Flowers | 11.30% | [ | ||
| Stems | 10.20% | [ | ||
| Geraniol | Aerial parts | 19.60% | Algeria | [ |
| Leaves | 7.30% | Morocco | [ | |
| Linalool | Aerial parts | 3.93% | Algeria | [ |
| 30.40% | [ | |||
| 47.30% | [ | |||
| 78.80% | [ | |||
| 22.15% | Tunisia | [ | ||
| 17.62% | [ | |||
| Leaves | 3.20% | [ | ||
|
| Aerial parts | 8.00% | Algeria | [ |
| 20.04% | [ | |||
| 14.70% | [ | |||
| 6.80% | [ | |||
| Leaves | 6.2-6.9%¥ | [ | ||
| 3% | [ | |||
| Aerial parts | 7.70% | Libya | [ | |
| 8.91% | [ | |||
| 23% | Morocco | [ | ||
| 27.18% | Tunisia | [ | ||
| Thymol | Aerial parts | 20.83% | Algeria | [ |
| 5.60% | [ | |||
| 20.20% | [ | |||
| 29.20% | [ | |||
| 62.70% | [ | |||
| Leaves | 71% | [ | ||
| Aerial parts | 56.00% | Libya | [ | |
| 38.50% | [ | |||
| 12.45% | [ | |||
| Aerial parts | 42% | Morocco | [ | |
| Aerial parts | 36.94% | Tunisia | [ | |
| Viridiflorol | Aerial parts | 4.00% | Algeria | [ |
| 0-11.49%∗ | Tunisia | [ | ||
| Roots | 17.20% | [ | ||
|
| Aerial parts | 6.80% | Algeria | [ |
| 27.14% | [ | |||
| Stem bark | 5.01% | [ | ||
| Aerial parts | 20.50% | Morocco | [ | |
| 20.50% | [ | |||
| 20.50% | [ | |||
| 7.41-13.94%∗ | Tunisia | [ | ||
| 21.31% | [ | |||
| 11.49% | [ | |||
| 15.50% | [ | |||
| Leaves | 19.50% | [ | ||
| 2.97% | [ | |||
| Leaves and flowers | 6.75% | [ | ||
|
| Aerial parts | 10.66% | Libya | [ |
| 3.24% | Tunisia | [ | ||
| 6.41% | [ | |||
|
| Aerial parts | 11.00% | Algeria | [ |
| Leaves | 3.0-3.4%¥ | [ | ||
|
| Aerial parts | 14.90% | Algeria | [ |
| Leaves | 5.9-6.7%¥ | [ | ||
| 0.50% | [ | |||
| Aerial parts | 7.19% | Libya | [ | |
| 9.90% | Tunisia | [ | ||
|
| Aerial parts | 4.00% | Algeria | [ |
| 3.39% | [ | |||
|
| Aerial parts | 9.68% | Algeria | [ |
|
| 47.40% | [ | ||
|
| 11.50% | [ | ||
| Bornyl acetate | 3.86-7.92%∗ | [ | ||
|
| 25.70% | [ | ||
| Germacrene D | 29.60% | [ | ||
| Neryl acetate | 9.60% | [ | ||
| Eucalyptol | 10.04% | [ | ||
| Bicyclogermacrene | 4.40% | [ | ||
| - | 7.80% | [ | ||
| 2,3-Dehydro-1,4-cineol | 36% | [ | ||
| Linalyl acetate | 6.39% | Tunisia | [ | |
|
| 5.72% | [ | ||
|
| 6.27% | [ | ||
|
| 3.15% | [ | ||
| Methyl eugenol | 6.78% | [ | ||
| Terpinen-4-ol | 6.80% | [ | ||
| Terpenyl acetate | 0-14.92%∗∗ | [ | ||
|
| 20.22% | Libya | [ | |
| Myrcene | 8.60% | Morocco | [ | |
| trans-Caryophyllene | Leaves | 2.40% | Morocco | [ |
| Geranyl acetate | 80.80% | [ | ||
| Acorenone | Stem bark | 5.84% | Algeria | [ |
∗Collected during the vegetative and flowering stages and from eight different geographic regions; ∗∗collected before, during, and after flowering stage; ¥effect of different gamma irradiation doses.
Figure 4Phenolic and carboxylic acids identified from T. algeriensis.
Figure 5Other compounds identified from T. algeriensis.
Figure 6Selected volatile compounds identified from T. algeriensis.
In vitro antioxidant activities of T. algeriensis extracts.
| Extract | Used method | Effects | Ref. |
|---|---|---|---|
|
| |||
| Aerial parts | |||
| PE, CHCl3, & n–BuOH | DPPH | IC50 (mg/mL) = 69.50 ± 0.68 (PE), 79.92 ± 0.30 (CHCl3), and 5.05 ± 0.12 (n–BuOH) | [ |
| CUPRAC | A0.50 ( | ||
| RP | A0.50 ( | ||
| TAC | TAC ( | ||
| FTC | %of inhibition = 27.80 ± 0.37 (PE), 24.25 ± 0.45 (CHCl3), and 47.43 ± 0.58 (n–BuOH) | ||
| EtOH & H2O | DPPH | IC50 (mg/mL) = 0.052 ± 0.004 (EtOH), not active (H2O) | [ |
| ABTS | IC50 ( | ||
| MeOH–H2O | DPPH | IC50 ( | [ |
| Iron chelating | EC50 ( | ||
|
| %of inhibition = 90 ± 2 | ||
| TAC | TAC ( | ||
| FRAP | FRAP (mM FeSO4/mg) = 5.3 ± 0.0 | ||
| H2O & EtOH–H2O | DPPH | EC50 ( | [ |
| RP | EC50 ( | ||
|
| EC50 ( | ||
| TBARS | EC50 ( | ||
| EA & n–BuOH | DPPH | EC50 (mg/mL) = 0.290 (EA) | [ |
| EO | DPPH | IC50 (mg/mL) = 10.2 ± 0.9–>45.0 | [ |
| Phosphomolybdenum assay | AEAC (mg/mL) = 0.148 ± 0.003–0.220 ± 0.022 | ||
| MeOH–H2O, acetone–H2O, MeOH, acetone–H2O | DPPH, ABTS, phosphomolybdenum | All extracts possess potential antioxidant activities compared to standards | [ |
| EO | TBARS | Not active | [ |
| ABTS | IC50 (mg/mL) = 0.150 ± 0.002 | ||
| DPPH | IC50 (mg/mL) = 0.235 ± 0.018 | ||
| ORAC | ORAC ( | ||
| RP | IC50 (mg/mL) = 0.025 ± 0.006 | ||
| Chelating metal ions | Not active | ||
| HRS | Not active | ||
| Superoxide anion scavenging assay (nonenzymatic method) | Not active | ||
| EO | HRS | IC50 ( | [ |
| DPPH | %of inhibition = 1.6 ± 0.0–53.4 ± 0.2 (chemotype and dose-dependent effect) | ||
| TBARS | IC50 ( | ||
| Leaves | |||
| MeOH | DPPH | EC50 ( | [ |
|
| %of inhibition = 64.31 ± 1.9 | ||
| Lipophilic extract using olive oil (OO) | RPlip | Significantly higher (RPlip = 50 mg BHT eq/g (dw)) than that of OO only (40 mg BHT eq/g OO) | [ |
| EtOH & EO | DPPH | IC50 (mg/mL) = 1.560 ± 0.010 (EtOH), 1.437 ± 4.51 (EO) | [ |
| ABTS | IC50 (mg/mL) = 1.743 ± 0.195 (EtOH), 0.8960 ± 0.203 (EO) | ||
| RP | AEAC–FRAP assay ( | ||
| Phosphomolybdenum | AEAC (mg/mL) = 0.007 ± 0.0006 (EtOH), 0.432 ± 0.001 (EO) | ||
| MeOH | DCFDA | No significant modification in ROS levels in HaCaT cells | [ |
| Western blot analyses | Significant increase in nuclear levels of Nrf–2 (nuclear factor erythroid 2) by up to 180% after incubation of the HaCaT cells for 15 min | ||
| H2O & EO | DPPH | IC50 (mg/L) = 404.08 ± 5.87 (EO), 22.26 ± 0.07 (H2O) | [ |
| ABTS | IC50 (mg/L) = 10.48 ± 0.49 (EO), 25.29 ± 0.21 (H2O) | ||
| TBARS | IC50 (mg/L) = 23.54 ± 0.37 (EO), not active (H2O) | ||
| RP | IC50 (mg/L) = 347.84 ± 3.02 (EO), 59.53 ± 0.70 (H2O) | ||
| EO | DPPH | IC50 (mg/mL) = 41.09 | [ |
| ABTS | IC50 (mg/mL) = 10.84 | ||
| TAC | TAC (U/L) = 39.27 ± 3.47 | ||
| Stem bark | |||
| EO | DPPH | IC50 (mg/mL) = 83.8 | [ |
|
| |||
| Aerial parts | |||
| EO | DPPH | IC50 (mg/mL) = 0.8 | [ |
|
| IC50 (mg/mL) = 0.5 | ||
| EO | DDPH | IC50 ( | [ |
| EO aqueous extract | DPPH | IC50 ( | [ |
| IC50 ( | |||
| H2O & hexane | DPPH | IC50 ( | [ |
| FRAP | Samples at vegetative and flowering stages (200, 300, 400, and 500 | ||
| EO | DPPH | %of inhibition = 52–91.96% | [ |
| EtOH & H2O | DPPH | IC50 ( | [ |
| FRAP | IC50 ( | ||
|
| IC50 ( | ||
| EO & MeOH | DPPH | %of inhibition = 81 ± 0.26–93 ± 0.06 (MeOH), 82 ± 0.52–85 ± 0.57 (EO) | [ |
| ABTS | %of inhibition = 22 ± 0.9–75 ± 0.72 (MeOH), 8 ± 0.7–19 ± 0.33 (EO) | ||
|
| %of inhibition = 25 ± 0.08–50 ± 0.12 (MeOH), 4 ± 0.44–10 ± 0.52 (EO) | ||
| Leaves | |||
| MeOH | DPPH | IC50 ( | [ |
| FRAP | EC50 (mmol Fe2+/L) = 1.0 ± 0.0–20.6 ± 0.2 | ||
|
| EC50 ( | ||
| EO | DPPH | IC50 (mg/mL) = 4.31 ± 0.7–9.23 ± 1.8 | [ |
| ABTS | ABTS ( | ||
| Leaves & flowers | |||
| EO | DPPH | IC50 ( | [ |
| MeOH & H2O | IC50 ( | [ | |
|
| |||
| Aerial parts | |||
| EA & MeOH | DPPH | IC50 ( | [ |
|
| IC50 ( | ||
| EO | DPPH | IC50 ( | [ |
| IC50 ( | [ | ||
| EO | DPPH | IC50 ( | [ |
| Leaves | |||
| H2O | DPPH | IC50 ( | [ |
| EO | DPPH | IC50 ( | [ |
| ABTS | IC50 ( | ||
|
| |||
| Aerial parts | |||
| EO | DPPH | EC50 (mg/mL) = 1.64 ± 0.05 | [ |
| RP | EC50 (mg/mL) = 0.68 ± 0.01 | ||
|
| EC50 (mg/mL) = 1.56 ± 0.12 | ||
| TBARS | EC50 (mg/mL) = 0.31 ± 0.01 | ||
| DPPH | EC50 (mg/mL) = 0.299 | [ | |
| DPPH | EC50 (mg/mL) = 0.132 | [ | |
ABTS: 2,2′-azino-bis 3-ethylbenzothiazoline-6-sulfonic acid; AEAC: ascorbic acid equivalent antioxidant capacity; BHT: butyl-hydroxytoluene; CUPRAC: cupric reducing antioxidant capacity; DCFDA: dichlorodihydrofluorescein diacetate; DPPH: 2,2-diphenyl-1-picryl-hydrazyl-hydrate; EA: ethyl acetate; EAA: equivalents of ascorbic acid; FRAP: ferric-reducing antioxidant power; FTC: ferric thiocyanate; HRS: hydroxyl radical scavenging; ORAC: oxygen radical absorbance capacity; PE: petroleum ether; RP: reducing power; TAC: total antioxidant capacity; TBARS: thiobarbituric acid reactive substances.
In vitro activities of T. algeriensis extracts.
| Extract | Activity | Used method | Country | Effects |
|
|---|---|---|---|---|---|
|
| |||||
| PE, CHCl3, and n–BuOH | Antihemolytic | Erythrocyte osmotic fragility | Algeria | IC50 ( | [ |
| Anti-inflammatory | Egg albumin denaturation | %inhibition = 30.26 (PE), 45.27 (CHCl3), 26.03 (n–BuOH) | |||
| EA & MeOH | Anticorrosive | Gravimetric and electrochemical | Morocco | %inhibition = 87% (MeOH) | [ |
| EO | Antitumor and cytotoxic | Sulforhodamine B | Libya | GI50 ( | [ |
| Hepatotoxicity evaluation | None of the EO showed toxicity at tested concentrations (>400 g/mL) for porcine liver primary cell culture | ||||
| EO | Anti-inflammatory | 5–Lipoxygenase | Algeria | IC50 ( | [ |
| EO | Leishmanicidal | MTT assay | Tunisia |
| [ |
|
| |||||
| Cytotoxic | IC80 ( | ||||
| EO | ACE inhibition | Spectrophotometry | Tunisia | IC50 ( | [ |
| EO | Anticorrosive | Weight loss measurement | Morocco | Inhibited the corrosion rate ( | [ |
| Potentiodynamic polarization | Acted as mixed-type inhibitor | ||||
| Electrochemical impedance spectroscopy | Inhibition efficiency ( | ||||
|
| |||||
| EO | Phytotoxic |
| Tunisia | 100% inhibition of | [ |
| Insecticidal | Fumigant bioassay against | LC50 ( | |||
| EO | Cytotoxic | Mitochondrial-dependent reduction of yellow | Algeria | LC50 ( | [ |
| LC50 and LC90 ( | |||||
| MeOH | COX inhibition | EIA | Algeria | IC50 ( | [ |
| LOX inhibition | Lipoxygenase inhibitor screening | IC50 ( | |||
| MeOH | Cytotoxic | MTT | Algeria | Biocompatible on both the immortalized tested cell lines HaCaT and BALB/c-3T3 and slightly toxic on A431 and SVT2 cancer cells at high concentrations (100 | [ |
| MeOH | Silver nanoparticle biosynthesis | Dropwise addition of the plant extract to the silver nitrate solution | Algeria | The extract acts as a reducing as well as a stabilizing agent | [ |
| EtOH and EO | Anticancer | MTT | Algeria | LC50 ( | [ |
| MeOH | Acetylcholinesterase inhibition | Spectrophotometry | Tunisia | %inhibition = 94.5% | [ |
|
| |||||
| MeOH & H2O | Cytotoxic | MTT | Tunisia | CC50 ( | [ |
| EO | Cytotoxic | MTT | Tunisia | CC50 ( | [ |
| EO | Anticancer | MTT | Morocco | Ta1 is more cytotoxic (100% lysis) than Tb2 (60% lysis) against P815 tumor cell line | [ |
| PBMC | Increased viability by 200% | ||||
ACE: angiotensin I-converting enzyme; CC: half maximal cytotoxic concentration; COX: cyclooxygenase; EIA: enzyme immunoassay; IC50: half maximal inhibitory concentration; IC80: concentration resulting in 80% inhibition; LC50: half maximal lethal concentration; LC90: concentration resulting in 90% lethality; LOX: lipoxygenase; MTT: methyl tetrazolium test; PBMC: peripheral blood mononuclear cells.
Antibacterial activities of T. algeriensis extracts.
| Extract | Tested strains | Key results | Ref. |
|---|---|---|---|
|
| |||
| MeOH–H2O |
| Resistant to all the extracts | [ |
|
| MIC ( | ||
|
| MIC ( | ||
|
| Resistant to all the extracts | ||
| EO |
| MBC (mg/mL) = 25, MIC (mg/mL) = 12.5 | [ |
|
| MBC (mg/mL) = 25, MIC (mg/mL) = 12.5 | ||
|
| MBC (mg/mL) = 25, MIC (mg/mL) = 3.12 | ||
|
| MBC (mg/mL) = 25, MIC (mg/mL) = 1.56 | ||
| EO |
| IZ (mm) = 18.0 ± 0.6 | [ |
|
| IZ (mm) = 18.0 ± 0.7 | ||
|
| IZ (mm) = 13.0 ± 0.9 | ||
| EO |
| MIC ( | [ |
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
| EO |
| MIC (%) = 0.025, MBC (%) = 0.05 | [ |
|
| MIC (%) = 0.020, MBC (%) = 0.05 | ||
|
| MIC (%) = 0.025, MBC (%) = 0.05 | ||
|
| MIC (%) = 0.025, MBC (%) = 0.05 | ||
|
| MIC (%) = 0.025, MBC (%) = 0.05 | ||
| MeOH–H2O |
| MIC (mg/mL) = 2.34 | [ |
|
| MIC (mg/mL) = 7.03 | ||
|
| MIC (mg/mL) = 4.68 | ||
|
| MIC (mg/mL) = 9.37 | ||
|
| MIC (mg/mL) = 7.06 | ||
| n–BuOH |
| IZ (mm) = 7 | [ |
|
| IZ (mm) = 6.5 ± 0.7 | ||
|
| IZ (mm) = 8 | ||
|
| IZ (mm) = 7 | ||
| EtOH & EO |
| MIC ( | [ |
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
| H2O & EO |
| IZ (mm) = 19–55 (H2O) | [ |
|
| IZ (mm) = 35–44 (EO) | ||
|
| IZ (mm) = 44–55 (EO) | ||
|
| IZ (mm) = 19–34 (EO) | ||
| MeOH & EtOH |
| IZ (mm) = 13 (MeOH), 10 (EtOH), MIC ( | [ |
|
| IZ (mm) = 0 (MeOH), 0 (EtOH), MIC ( | ||
|
| IZ (mm) = 16.5 (MeOH), 14 (EtOH), MIC ( | ||
|
| IZ (mm) = 9 (MeOH), 12 (EtOH), MIC ( | ||
|
| IZ (mm) = 7 (M), 0 (EtOH), MIC ( | ||
|
| IZ (mm) = 12.5 (MeOH), 17 (EtOH), MIC ( | ||
|
| IZ (mm) = 19 (MeOH), 15.5 (EtOH), MIC ( | ||
| EO, EtOH, & H2O |
| IZ (mm) = 11.53 ± 0.43 (EO), 10.91 ± 0.05 (EtOH) | [ |
|
| IZ (mm) = 11.52 ± 0.41 (EO) | ||
|
| IZ (mm) = 0 (EO) | ||
|
| IZ (mm) = 12.51 ± 0.19 (EO) | ||
| EtOH–H2O & H2O |
| MIC (mg/mL) = 10 (H2O)–5 (EtOH–H2O) | [ |
|
| MIC (mg/mL) = 20 (H2O)–20 (EtOH–H2O) | ||
|
| MIC (mg/mL) = 5 (H2O)–5 (EtOH–H2O) | ||
|
| MIC (mg/mL) = 5 (H2O)–5 (EtOH–H2O) | ||
|
| MIC (mg/mL) = 10 (H2O)–5 (EtOH–H2O) | ||
|
| MIC (mg/mL) = 10 (H2O)–5 (EtOH–H2O) | ||
|
| MIC (mg/mL) = 10 (H2O)–10 (EtOH–H2O) | ||
|
| MIC (mg/mL) = 10 (H2O)–10 (EtOH–H2O) | ||
|
| MIC (mg/mL) = 5 (H2O)–2.5 (H2O & H2O) | ||
|
| MIC (mg/mL) = 5 (H2O)–2.5 (H2O & H2O) | ||
| EO |
| IZ (mm) = 28 ± 1.5 | [ |
|
| IZ (mm) = 20 ± 1.73 | ||
|
| IZ (mm) = 12 ± 1.33 | ||
|
| IZ (mm) = 13 ± 1 | ||
| EO |
| IZ (mm) = 10–13 | [ |
|
| IZ (mm) = 8–36 | ||
|
| IZ (mm) = 10–13 | ||
|
| IZ (mm) = 0 | ||
| H2O & MeOH |
| MIC (mg/mL) = 0.25–0.5 (H2O), 0.12–0.25 (MeOH) | [ |
|
| MIC (mg/mL) = 0.12–0.5 (H2O), 0.12–0.25 (MeOH) | ||
|
| MIC (mg/mL) = 0.5–1 (H2O), 1 (MeOH) | ||
|
| MIC (mg/mL) = 0.12–0.5 (H2O), 0.5–1 (MeOH) | ||
| EO |
| MIC (mg/mL) = 0.08 ± 0.03, MBC (mg/mL) = 0.15 ± 0.05 | [ |
|
| MIC (mg/mL) = 0.09 ± 0.04, MBC (mg/mL) = 0.18 ± 0.07 | ||
|
| MIC (mg/mL) = 0.05 ± 0.04, MBC (mg/mL) = 0.11 ± 0.07 | ||
|
| MIC (mg/mL) = 0.08 ± 0.03, MBC (mg/mL) = 0.11 ± 0.07 | ||
|
| MIC (mg/mL) = 0.05 ± 0.00, MBC (mg/mL) = 0.11 ± 0.01 | ||
|
| MIC (mg/mL) = 0.04 ± 0.00, MBC (mg/mL) = 0.09 ± 0.02 | ||
|
| MIC (mg/mL) = 0.03 ± 0.00, MBC (mg/mL) = 0.05 ± 0.00 | ||
|
| MIC (mg/mL) = 0.04 ± 0.01, MBC (mg/mL) = 0.08 ± 0.02 | ||
| EO |
| MIC (mg/mL) = 2.5 mg/mL | [ |
|
| MIC (mg/mL) = 1.66 mg/mL | ||
|
| MIC (mg/mL) = 0.20 mg/mL | ||
| EO |
| MIC (mg/mL) = 2.030–2.114, MBC (mg/mL) ≥ 4.227 | [ |
|
| MIC (mg/mL) ≥ 4.227, MBC (mg/mL) ≥ 4.227 | ||
|
| MIC (mg/mL) = 2.114–3.004, MBC (mg/mL) = 4.059–3.044 | ||
|
| MIC (mg/mL) = 3.004–3.044, MBC (mg/mL) ≥ 4.059 | ||
|
| MIC (mg/mL) = 0.264–1.015, MBC (mg/mL) = 0.528–1.015 | ||
|
| MIC (mg/mL) = 1.015–1.057, MBC (mg/mL) = 1.015–1.057 | ||
|
| MIC (mg/mL) = 0.528–1.015, MBC (mg/mL) = 2.030–3.044 | ||
|
| MIC (mg/mL) = 0.507–0.528, MBC (mg/mL) = 1.015–1.057 | ||
| EO |
| MIC (mg/mL) = 1.80–4.20 | [ |
|
| MIC (mg/mL) = 0.90–0.90 | ||
|
| MIC (mg/mL) = 1.50–22.00 | ||
|
| MIC (mg/mL) = 1.70–4.50 | ||
|
| MIC (mg/mL) = 4.00–5.50 | ||
|
| MIC (mg/mL) = 2.00–7.50 | ||
| EO |
| MIC ( | [ |
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
| EO |
| MIC (mg/mL) = 0.002, MBC (mg/mL) = 0.004 | [ |
|
| MIC (mg/mL) = 0.003, MBC (mg/mL) = 0.05 | ||
|
| MIC (mg/mL) = 0.05, MBC (mg/mL) = 0.05 | ||
|
| MIC (mg/mL) = 0.003, MBC (mg/mL) = 0.05 | ||
|
| MIC (mg/mL) = 0.001, MBC (mg/mL) = 0.05 | ||
|
| MIC (mg/mL) = 0.001, MBC (mg/mL) = 0.0025 | ||
|
| MIC (mg/mL) = 0.001, MBC (mg/mL) = 0.0025 | ||
|
| MIC (mg/mL) = 0.002, MBC (mg/mL) = 0.003 | ||
| EO |
| Inactivation of 5 log10 cycles of | [ |
|
| |||
| EO |
| IZ (mm) = 15.6 ± 2.4 | [ |
|
| IZ (mm) = 17.8 ± 1.7 | ||
|
| IZ (mm) = 15.2 ± 1.0 | ||
|
| IZ (mm) = 51.0 ± 3.4 | ||
|
| IZ (mm) = 14.7 ± 1.2 | ||
|
| IZ (mm) = 26.7 ± 2.3 | ||
|
| IZ (mm) = 33.7 ± 0.4 | ||
| EO |
| IZ (mm) = 14 ± 1 mm, MIC ( | [ |
|
| IZ (mm) = 14.5 ± 0.5 mm, MIC ( | ||
|
| IZ (mm) = 13.5 ± 0.5 mm, MIC ( | ||
|
| IZ (mm) = 15 ± 0.5 mm, MIC ( | ||
|
| IZ (mm) = 30 ± 2 mm, MIC ( | ||
|
| IZ (mm) = 18.5 ± 0.5 mm, MIC ( | ||
| EO |
| MIC ( | [ |
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
| EO |
| IZ (mm) = 9.33 mm | [ |
|
| IZ (mm) = 11.66 mm | ||
|
| IZ (mm) = 17.00 mm | ||
|
| IZ (mm) = 8.33 mm | ||
|
| IZ (mm) = 13–30 mm | ||
| EO |
| IZ (mm) = 42 mm, MIC ( | [ |
|
| IZ (mm) = 0 mm, MIC ( | ||
|
| IZ (mm) = 0 mm, MIC ( | ||
|
| IZ (mm) = 0 mm, MIC ( | ||
|
| |||
| H2O |
| Not active towards any of the microorganisms | [ |
|
| |||
|
| |||
|
| |||
| MeOH |
| MIC (mg/mL) = 1.4 | [ |
|
| MIC (mg/mL) = 1.4 | ||
|
| MIC (mg/mL) = 1.4 | ||
|
| MIC (mg/mL) = 1.4 | ||
|
| MIC (mg/mL) = 1.4 | ||
|
| MIC (mg/mL) = 1.4 mg/mL, MBC (mg/mL) = 1.4 | ||
|
| MIC (mg/mL) = 1.4 | ||
| EO |
| MIC ( | [ |
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
|
| MIC ( | ||
| EO |
| IZ (mm) = 25 | [ |
|
| IZ (mm) = 46 | ||
|
| IZ (mm) = 75 | ||
|
| IZ (mm) = 15 | ||
|
| IZ (mm) = 60 | ||
|
| IZ (mm) = 28 | ||
|
| IZ (mm) = 25 | ||
|
| IZ (mm) = 49 | ||
|
| |||
| EO |
| MIC (mg/mL) = 0.5 | [ |
|
| MIC (mg/mL) = 0.5 | ||
|
| MIC (mg/mL) = 0.5 | ||
|
| MIC (mg/mL) = 0.5 | ||
|
| |||
| EO |
| Inactivation of the initial cell populations by 4–5 log10 cycles in combination with high hydrostatic pressure | [ |
|
| |||
IC50: half-maximal inhibitory concentration; IZ: inhibition zone; MBC: minimum bactericidal concentration; MIC: minimum inhibitory concentration; MRSA: meticillin-resistant Staphylococcus aureus; MSSA: meticillin-sensitive Staphylococcus aureus.
Antifungal activities of T. algeriensis extracts.
| Tested strains | Key results | Ref. |
|---|---|---|
| Aerial parts | ||
| EO | ||
| | IZ (mm) = 2.04 ± 0.8 | [ |
| | IZ (mm) = 13.0 ± 0.4 | |
| | IZ (mm) = 18.0 ± 0.6 | |
| | MIC ( | [ |
| | MIC (mg/mL) = 0.01 ± 0.00, MFC (mg/mL) = 0.03 ± 0.00 | [ |
| | MIC (mg/mL) = 0.04 ± 0.01, MFC (mg/mL) = 0.04 ± 0.03 | |
| | MIC (mg/mL) = 0.01 ± 0.00, MFC (mg/mL) = 0.03 ± 0.00 | |
| | MIC (mg/mL) = 0.01 ± 0.00, MFC (mg/mL) = 0.01 ± 0.00 | |
| | MIC (mg/mL) = 0.01 ± 0.00, MFC (mg/mL) = 0.01 ± 0.00 | |
| | MIC (mg/mL) = 0.01 ± 0.01, MFC (mg/mL) = 0.03 ± 0.02 | |
| | MIC (mg/mL) = 0.01 ± 0.02, MFC (mg/mL) = 0.03 ± 0.02 | |
| | MIC (mg/mL) = 0.02 ± 0.01, MFC (mg/mL) = 0.04 ± 0.01 | |
| | MIC (mg/mL) = 4.510–4.697, MFC (mg/mL) ≥ 4.697 | [ |
| | EO at 0.5% decreased the rate of infestation and caused a mortality rate of 32.6% | [ |
| | IC50 ( | [ |
| | IC50 ( | |
| | IC50 ( | |
| | IC50 ( | |
| | IC50 ( | |
| | MIC ( | [ |
| | MIC ( | |
| | MIC (mg/mL) = 0.002, MFC (mg/mL) = 0.004 | [ |
| | MIC (mg/mL) = 0.002, MFC (mg/mL) = 0.003 | |
| | MIC (mg/mL) = 0.001, MFC (mg/mL) = 0.003 | |
| | MIC (mg/mL) = 0.001, MFC (mg/mL) = 0.0025 | |
| | MIC (mg/mL) = 0.001, MFC (mg/mL) = 0.002 | |
| | MIC (mg/mL) = 0.001, MFC (mg/mL) = 0.0025 | |
| | MIC (mg/mL) = 0.0005, MFC (mg/mL) = 0.001 | |
| | MIC (mg/mL) = 0.025, MFC (mg/mL) = 0.05 | |
| | IZ (mm) = 31 ± 1.5, MIC ( | [ |
| | IZ (mm) = 64 ± 3, MIC ( | |
| | MIC ( | [ |
| | MIC ( | |
| | MIC ( | |
| | MIC ( | [ |
| | MIC ( | |
| | MIC ( | |
| | MIC ( | |
| | IZ (mm) = 9.66 | [ |
| | IZ (mm) = 9.33 | |
| | IZ (mm) = 32, MIC ( | [ |
| | IZ (mm) = 46, MIC ( | |
| | IZ (mm) = 28, MIC ( | |
| | IZ (mm) = 34, MIC ( | |
| EtOH & EO | ||
| | MIC ( | [ |
| | MIC ( | |
| H2O & MeOH | ||
| | %inhibition = 5.33 ± 1.15–8 ± 2 (H2O), 0–11.33 ± 1.15 (MeOH) | [ |
| | %inhibition = 46.03 ± 2.74–63.83 ± 6.88 (H2O), 42.53 ± 0.54–75.04 ± 4.12 (MeOH) | |
| Leaves | ||
| H2O | ||
| | Not active | [ |
| EO | ||
| | IZ (mm) = 23 | [ |
| | IZ (mm) = 47 | |
| H2O & EtOH | ||
| | EC50 = 32.35 ± 2.02 (H2O), EC90 = 112.55 ± 16.57 (H2O) | [ |
| EC50 = 1.32 ± 0.4 (EtOH), EC90 = 24.97 ± 4.9 (EtOH) | ||
| Leaves & Flowers | ||
| EO | ||
| | Not active | [ |
| | 42.86% inhibition |
EC50: half maximal effective concentration; EC90: 90% maximal effective concentration; IC50: half maximal inhibitory concentration; IZ: inhibition zone; MBC: minimum bactericidal concentration; MFC: minimum fungicidal concentration; MIC: minimum inhibitory concentration.
In vivo activities of T. algeriensis extracts.
| Extract | Doses | Model | Activity | Effects | Ref. |
|---|---|---|---|---|---|
|
| |||||
| Leaves | |||||
| 80% MeOH | 200, 400, and 600 mg/kg | Male rats | Anti-inflammatory activity | Significant mild reduction in edema thickness using 400 mg/kg by up to 30% | [ |
| Leukocyte's recruitment | A dose-dependent reduction in the total leukocyte number at three doses tested by up to 62% | ||||
| 200, 400, and 600 mg/kg | Swiss albino mice | Acetic acid-induced vascular permeability | Attenuation of vasodilation and decreased vascular permeability in mice at 400 or 600 mg/kg by 63 and 58%, respectively | ||
| 200 and 400 mg/kg | Antinociceptive activity by hot plate test | A dose-dependent increase in response latency using 200 and 400 mg/kg by up to 200% | |||
| 200 and 400 mg/kg | Antinociceptive activity by acetic acid-induced abdominal writhing | 94% reduction of the writhing response using 400 mg/kg | |||
| 200 and 400 mg/kg | Male Wistar rats | Heat hyperalgesia | Restoration of heat response latency when measured at day 14 post chronic constriction injury (CCI) by about 160 and 200% using 200 and 400 mg/kg, respectively | [ | |
| Mechanical hyperalgesia (pinprick test) | Increased the withdrawal time of injured hind paw by 8.4- and 6-folds after 7 and 14 days, respectively | ||||
| Acetone drop test (paw cold allodynia) | Decreased cold allodynia score by about 16- and 10-folds after 7 and 14 days using 200 and 400 mg/kg, respectively | ||||
| Paint-brush test (mechanical dynamic allodynia) | Attenuated the dynamic allodynia score when assessed at day 7 by up to 1.75-folds | ||||
| Aqueous extract | 2000 and 5000 mg/kg | Albino Wistar rats | Acute toxicity study for 14 days | No mortality or signs of toxicity and no significant differences in body weight, food consumption, and absolute organ weights between controls and treated animals | [ |
|
| |||||
| Aerial part | |||||
| MeOH–H2O | 200, 400, and 800 mg/kg | Albino male mice | Safety evaluation | No influence on the levels of AST and ALT | [ |
| Antioxidant activity | Increased the plasma antioxidant levels by 3-folds (22% of inhibition) using 800 mg/kg | ||||
| Increased the iron reducing ability (908 | |||||
|
| |||||
| Aerial part | |||||
| EO | 180 mg/kg per day dissolved in normal saline | Sprague Dawley rats | Body weight gain, toxicity, and mortality | Body weight gain, no mortality, and no sign of toxicity after 15 days of experiment | [ |
| Assessment of lipid profile | Decreased the MDA levels (743.57 ± 41.12 nmol MDA/mg protein) compared to the control group (3648.47 ± 33.22 nmol MDA/mg protein) | ||||
| Assessment of antioxidant defense enzymes | Prevented the toxicity effect of H2O2 on the nonenzymatic antioxidant GSH level and the activities of SOD, CAT, GPx, and GST | ||||
| Histopathological examination | No pathological change, normal histoarchitecture, and significant reduction in neuronal damage induced by H2O2 | ||||
| AChE inhibition | Decreased the AChE activity by up to 31.5% | ||||
| 150 mg/kg | Adult male Wistar rats | Reproductive organs weights | Weight gain by up to 92% | [ | |
| Sperm morphology | No effect on sperm's morphology, counts, and mobility | ||||
| Sperm count and motility | |||||
| Sperm viability | Increased the sperm's viability by up to 46% | ||||
| Histopathological studies | Improvement in morphological abnormalities (amorphous head, hookless head, doublet heads, compact head tail with a cytoplasmic droplet, irregular tail, and coiled tail) of sperms | ||||
| DNA fragmentation analysis using gel electrophoresis | Protection against H2O2-induced DNA fragmentation in testis | ||||
| Lipid peroxidation | Reduction of the levels of MDA in testicular cells induced by H2O2 at 1 mmol/L | ||||
| Assessment of nonenzymatic antioxidants | Prevention of the H2O2-induced alterations in GSH level | ||||
| Protein estimation | Increase in total protein | ||||
| 180 mg/kg per day | Sprague Dawley rats | Hepatic and renal functional marker enzymes | Attenuation of the increase in AST and reduction in urea and creatinine levels in H2O2-treated group | [ | |
| Enzymatic antioxidants and lipid profile | Recovered the levels of CAT (up to 150% increase), SOD (up to 233% increase), GST (up to 15.7% increase) and GPx (up to 71.4% increase) activities, and GSH (up to 98% increase) | ||||
| Histopathological examination | No histopathological changes in the liver and kidney | ||||
| Body and organ weights | Prevention of H2O2-induced liver, kidney, and weight loss | ||||
| 54, 117, and 180 mL/kg | Adult male and female Wistar rats | Histology of gastric lesions | Lesions inhibition mainly at doses of 180 mg/kg for male rats (88%) and between 117 and 180 mg/kg for female rats (96.25 and 98.85%) | [ | |
| Assessment of enzymatic and nonenzymatic antioxidants | Increase in SOD, CAT, GPx, and GST activities and GSH content | ||||
| Measurement of mucus production | Increase in the mucus production of gastric mucosa compared to control group | ||||
| Acute toxicity study in rodents | No signs of toxicity and absence of abnormal organic damage to the rats' organs | ||||
AChE: acetylcholine; ALP: alanine transaminase; AST: aspartate transaminase; CAT: catalase; CCI: chronic constriction injury; CDNB: 2,4-dinitrochlorobenzene; GPx: glutathione peroxidase; GSH: glutathione; GST: glutathione S-transferases; MDA: malondialdehyde; SOD: superoxide dismutase. All experiments were done orally.
Figure 7Coword map network visualization of T. algeriensis.
Figure 8Knowledge map of T. algeriensis.
Figure 9Mechanisms of antioxidant and anti-inflammatory effects of T. algeriensis extracts. Oxidative stress is associated with increased lipid peroxidation product (MDA) and decreased antioxidant enzyme activities such as SOD, GST, and CAT and nonenzymatic antioxidants such as GSH. Increased oxidative stress is a trigger for release of inflammatory cytokines such as TNF-α and IL-1β which increase p38 and subsequent phosphorylation and translocation of NF-κB to the nucleus and subsequent transcription of genes responsible for formation of inflammatory cytokines creating a vicious cycle of inflammation. Furthermore, oxidative stress activates inflammatory enzymes such as LOX and COX with subsequent increase in both leukotriene and PG syntheses, respectively. T. algeriensis through its potent antioxidant effects can suppress all these inflammatory pathways and thus protect susceptible tissues against oxidative and inflammatory reactions. Abbreviations: LOX: lipoxygenase; COX: cyclooxygenase; LT: leukotrienes; PGE2: prostaglandin E2; GSH: reduced glutathione; GST: glutathione transferase; CAT: catalase; SOD: superoxide dismutase; MDA: malondialdehyde; IL-1β: interleukin-1β; IL-6: interleukin-6; NF-κB: nuclear factor kappa B; Nrf–2: nuclear factor erythroid 2; p38: mitogen-activated protein kinase; TNF-α: tumor necrosis factor.